Niagen Bioscience Inc (FRA:OCD1) Stock Price, Trades & News

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	25.78
Equity-to-Asset	0.72
Debt-to-Equity	0.03
Debt-to-EBITDA	0.2
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	5/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	5.55	Distress Grey Safe
Beneish M-Score	0.38	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

7/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	13.6
	3-Year Book Growth Rate	35.6
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	21.9
	Future 3-5Y Total Revenue Growth Rate Estimate	15.14

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	41.59
	9-Day RSI	44.83
	14-Day RSI	45.61
	3-1 Month Momentum %	-36.68
	6-1 Month Momentum %	-49.6
	12-1 Month Momentum %	-68.7

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.61
	Quick Ratio	3.55
	Cash Ratio	2.91
	Days Inventory	139.2
	Days Sales Outstanding	26.88
	Days Payable	95.79

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.2
	Shareholder Yield %	0.94

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	64.28
	Operating Margin %	8.51
	Net Margin %	14.29
	EBITDA Margin %	9.7
	FCF Margin %	3.12
	OCF Margin %	3.37
	ROE %	26.69
	ROA %	18.95
	ROIC %	66.26
	3-Year ROIIC %	496.74
	ROC (Joel Greenblatt) %	88.13
	ROCE %	14.49
	Years of Profitability over Past 10-Year	2
	Moat Score	4
	Tariff Resilience Score	4

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	15.67
	Forward PE Ratio	13.1
	PE Ratio without NRI	20.96
	Price-to-Owner-Earnings	71.52
	PS Ratio	2.16
	PB Ratio	3.18
	Price-to-Tangible-Book	3.4
	Price-to-Free-Cash-Flow	70
	Price-to-Operating-Cash-Flow	64.51
	EV-to-EBIT	17.86
	EV-to-EBITDA	15.67
	EV-to-Forward-EBITDA	11.87
	EV-to-Revenue	1.52
	EV-to-Forward-Revenue	1.36
	EV-to-FCF	48.27
	Price-to-GF-Value	0.64
	Price-to-Projected-FCF	8.89
	Price-to-Median-PS-Value	0.41
	Price-to-Graham-Number	1.78
	Price-to-Net-Current-Asset-Value	3.57
	Price-to-Net-Cash	7.65
	Earnings Yield (Greenblatt) %	5.6
	FCF Yield %	1.57

Financials (Next Earnings Date:2026-08-04)

Annual Quarterly TTM

FRA:OCD1's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Niagen Bioscience Inc Executives

Details

GF Value™: €3.98

FRA:OCD1

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with OCD1. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	112.058
	EPS (TTM) (€)	0.182
	Beta	1.007
	3-Year Sharpe Ratio	0.53
	3-Year Sortino Ratio	1.42
	Volatility %	42.27
	14-Day RSI	45.61
	14-Day ATR (€)	0.12768
	20-Day SMA (€)	2.691
	12-1 Month Momentum %	-68.7
	52-Week Range (€)	2.46 - 9.55
	Shares Outstanding (Mil)	79.64

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	5
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Niagen Bioscience Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Niagen Bioscience Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-04 16:30	In 99 days
Third quarter earnings results for 2026	2026-11-04	In 98 days
Niagen Bioscience to Present at Canaccord Genuity’s 46th Annual Growth Conference	2026-08-11 14:00	In 14 days
Second quarter earnings conference call for 2026	2026-08-04 16:30	In 7 days
Second quarter earnings results for 2026	2026-08-04	In 6 days
KCSA Strategic Communications	2026-07-15 08:00	2.80 (+0.00%)
General meeting for 2026	2026-06-24 15:00	2.72 (+0.00%)
First quarter earnings conference call for 2026	2026-05-06 16:30	3.98 (+0.00%)
First quarter earnings results for 2026	2026-05-06	3.98 (+0.00%)
38th Annual ROTH Conference	2026-03-23 17:00	3.82 (+0.00%)

Show

Entries

Niagen Bioscience Inc Frequently Asked Questions

What is Niagen Bioscience Inc(FRA:OCD1)'s stock price today?

The current price of FRA:OCD1 is €2.58. The 52 week high of FRA:OCD1 is €9.55 and 52 week low is €2.46.

When is next earnings date of Niagen Bioscience Inc(FRA:OCD1)?

The next earnings date of Niagen Bioscience Inc(FRA:OCD1) is 2026-08-04.

Does Niagen Bioscience Inc(FRA:OCD1) pay dividends? If so, how much?

Niagen Bioscience Inc(FRA:OCD1) does not pay dividend.

Press Release

	Subject	Date
	Niagen Bioscience Announces a Newly Published Analysis of Past Clinical Studies Demonstrating Niagen® (Patented Nicotinamide Riboside, NR) Supplementation Improved a Muscle-Specific Marker of Biologic	2026-07-28
	Niagen Bioscience to Present at Canaccord Genuity's 46th Annual Growth Conference	2026-07-27
	Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026	2026-07-21
	Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia	2026-07-13
	Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026	2026-07-09
	Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases	2026-07-08
	Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science	2026-06-02
	Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™	2026-04-28
	Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026	2026-04-22
	Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®	2026-04-09

10/Page

Articles on Niagen Bioscience Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.